NCT00567424撤回2 期
An Open-label Evaluation of Drug Interactions, Safety, Tolerability and Efficacy of GW273225 Add-on Treatment of Partial Seizures, Whether or Not Secondarily Generalized
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 31
- 主要终点
- Pharmacokinetic drug interactions with the most common inhibiting and inducing antiepileptic drugs AEDs: valproate(VPA), carbamazepine(CBZ) and phenytoin (PHT).
研究概览
简要总结
Study to determine drug interactions between GW273225 and the anticonvulsants valproate, carbamazepine or phenytoin
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Pharmacokinetic drug interactions with the most common inhibiting and inducing antiepileptic drugs AEDs: valproate(VPA), carbamazepine(CBZ) and phenytoin (PHT).
次要结局
- Safety/tolerability of GW273225 in adults with refractory epilepsy Efficacy of GW273225 in adults with refractory epilepsy Potential initial starting doses for a subsequent placebo-controlled dose-ranging Phase IIb study.
研究者
研究点 (31)
Loading locations...
相似试验
已完成
1 期
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsHealthyNCT06370728Eli Lilly and Company30
已完成
1 期
GSK1349572 Drug Interaction Study With EtravirineHealthy SubjectsNCT00774111GlaxoSmithKline16
已完成
1 期
GSK1349572 Drug Interaction Study With Protease InhibitorsHealthy SubjectsInfection, Human Immunodeficiency VirusNCT00774735GlaxoSmithKline30
已完成
1 期
GSK1349572 Drug Interaction With TenofovirHealthy SubjectsNCT00726336GlaxoSmithKline16
已完成
1 期
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.Diabetes Mellitus Type 2NCT00388986Hoffmann-La Roche18